Risk Management and Governance Look Smart at a $240bn Pharmaceutical Company
Whether You Build It Or Buy It, You Probably Need to Do It.
Whether You Build It Or Buy It, You Probably Need to Do It.
In this episode, not to be outclassed as investors comment on Astrazeneca's brilliant resilience insurance solution, a competitor takes action.
Links pertaining to this episode:
The podcast is produced by Steel City Re.
Get new episodes of 5-Minute Aventures in Risk & Resilience automatically
